KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

Innovation: over 500 UK patients gain early access to new skin cancer treatment

MSD successfully put their advanced new melanoma treatment through MHRA's early access to medicine scheme (EAMS).

Speeding up patient access to new, promising, innovative treatments is a current priority for the UK government, regulatory agencies and the pharmaceutical industry.

MHRA’s early access to medicines scheme (EAMS) aims to offer patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.

MSD (known as Merck & Co Inc. in the United States and Canada), works to address unmet health needs through the development of innovative medicines, vaccines, biological therapies and animal health products. Pembrolizumab was being developed as a treatment for advanced melanoma (skin cancer), where MSD had identified an unmet clinical need.

Through EAMSMHRA has been able to work with MSD to ensure that UK patients with advanced melanoma have been among the first in the world to access the breakthrough treatment, pembrolizumab. This has enabled approximately 500 patients with advanced melanoma with limited treatment options to benefit from the treatment prior to licence and paved the way for accelerated routine access in the NHS.

In June 2014, phase 1 clinical trial data published by the American Society of Clinical Oncology (ASCO) pointed to the significant health improvements exhibited by patients who had been provided with pembrolizumab as treatment for advanced melanoma. These exciting results helped to confirm that pembrolizumab could address an unmet medical need.

However, patients who required the treatment would need access to pembrolizumab in the intervening time between clinical trials completing, when the treatment meets with regulatory approval and is licensed, and when the treatment is finally available for routine use – a process that can often take several months and that can affect seriously-ill patients who cannot afford the time to wait for treatment.

 

In October 2014, MSD requested that MHRA consider accepting pembrolizumab into EAMS and worked with a series of co-ordinated stakeholders to progress their treatment through the scheme, including:MHRA, National Institute for Health and Care Excellence (NICE), NHS in England, Northern Ireland, Scotland and Wales.

For more details on how MHRA helped click here